English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Clinical characteristics of pain in patients with pituitary adenomas

MPS-Authors
/persons/resource/persons80305

Dimopoulou,  C.
Dept. Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons124315

Athanasoulia,  A. P.
Dept. Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons172907

Hanisch,  E.
Dept. Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80539

Stalla,  G. K.
Dept. Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80528

Sievers,  C.
Dept. Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Dimopoulou, C., Athanasoulia, A. P., Hanisch, E., Held, S., Sprenger, T., Toelle, T. R., et al. (2014). Clinical characteristics of pain in patients with pituitary adenomas. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 171(5), 581-591. doi:10.1530/EJE-14-0375.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0026-DCA0-E
Abstract
Objective: Clinical presentation of pituitary adenomas frequently involves pain, particularly headache, due to structural and functional properties of the tumour. Our aim was to investigate the clinical characteristics of pain in a large cohort of patients with pituitary disease. Design: In a cross-sectional study, we assessed 278 patients with pituitary disease (n=81 acromegaly; n=45 Cushing's disease; n=92 prolactinoma; n=60 non-functioning pituitary adenoma). Methods: Pain was studied using validated questionnaires to screen for nociceptive vs neuropathic pain components (painDETECT), determine pain severity, quality, duration and location (German pain questionnaire) and to assess the impact of pain on disability (migraine disability assessment, MIDAS) and quality of life (QoL). Results: We recorded a high prevalence of bodily pain (n=180, 65%) and headache (n=178, 64%); adrenocorticotropic adenomas were most frequently associated with pain (n= 34, 76%). Headache was equally frequent in patients with macro- and microadenomas (68 vs 60%; P=0.266). According to painDETECT, the majority of the patients had a nociceptive pain component (n=193, 80%). Despite high prevalence of headache, 72% reported little or no headache-related disability (MIDAS). Modifiable factors including tumour size, genetic predisposition, previous surgery, irradiation or medical therapy did not have significant impact neither on neuropathic pain components (painDETECT) nor on headache-related disability (MIDAS). Neuropathic pain and pain-related disability correlated significantly with depression and impaired QoL. Conclusions: Pain appears to be a frequent problem in pituitary disease. The data suggest that pain should be integrated in the diagnostic and therapeutic work-up of patients with pituitary disease in order to treat them appropriately and improve their QoL.